PRN Archives - BioTuesdays

Developments

Emmy-Award Winning TV host Montel Williams to join Profound’s next ‘Let’s Huddle’ webinar; company confirms first TULSA-PRO install at a VA facility

Profound Medical (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let’s Huddle...

October 22, 2026

Developments

Profound’s TULSA abstracts at the 15th iMRI Symposium strengthen real-world evidence, clinical differentiation, and platform expansion opportunity

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that five abstracts presented at the 15th Interventional MRI (iMRI) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real...

October 14, 2026

Developments

Profound Medical and Telix Pharmaceuticals enter co-education agreement to advance PSMA-informed, MRI-guided and incisionless prostate care

Profound Medical (NASDAQ:PROF; TSX:PRN) and Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) have entered into a co-education agreement which establishes a framework through which the companies intend to educate urologists...

October 9, 2026

Developments

Profound reports record preliminary Q3-2026 revenue; expects up to 89% YoY and 300% sequential QoQ growth; preliminary numbers exceed Bloomberg analyst consensus by 45% to 47%

Profound Medical (NASDAQ: PROF; TSX: PRN) announced preliminary unaudited revenues for the third quarter of 2026. The company indicated that its: Total revenue is expected to be in the range of $9.8 million to $10.0...

October 8, 2026

Developments

Profound Medical’s new president makes open market purchase of company shares

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) president, Richard Fabian, acquired a total of 10,000 shares of Profound on the open market today at a cost of $59,800 (U.S.). In a sign of...

September 17, 2026

Markets

Titan starts Profound Medical at buy; PT $12

Titan Partners initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and price target of $12.00. The stock closed at $5.96 on Sept 10. Profound is a commercial-stage medical device company...

September 11, 2026

Executive Moves

Profound strengthens leadership team with appointment of Richard Fabian as president

Profound Medical (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, succeeding Mathieu Burtnyk, PhD, who has assumed the newly created position of chief technology officer. Mr...

September 1, 2026

Developments

Profound’s new real-time interventional MRI software to pave the way for full ‘TULSA days’

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the introduction of its latest Treatment Delivery Console (TDC) software being deployed across Profound’s TULSA-PRO-installed base. According to Profound, the TDC...

August 17, 2026

Developments

Profound launches ‘Let’s Huddle’, a global community supporting men through prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the launch of Let’s Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every...

August 14, 2026

Developments

Incisionless TULSA Procedure for prostate cancer demonstrated statistically significant superior penile length preservation compared to Robotic Radical Prostatectomy at 1 month

The title of Profound Medical’s (NASDAQ:PROF; TSX:PRN) press release today, “Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial,” playfully set the tone for its reporting of a sensitive subject: penile...

July 24, 2026

Tag - PRN

Emmy-Award Winning TV host Montel Williams to join Profound’s next ‘Let’s Huddle’ webinar; company confirms first TULSA-PRO install at a VA facility

Profound’s TULSA abstracts at the 15th iMRI Symposium strengthen real-world evidence, clinical differentiation, and platform expansion opportunity

Profound Medical and Telix Pharmaceuticals enter co-education agreement to advance PSMA-informed, MRI-guided and incisionless prostate care

Profound reports record preliminary Q3-2026 revenue; expects up to 89% YoY and 300% sequential QoQ growth; preliminary numbers exceed Bloomberg analyst consensus by 45% to 47%

Profound Medical’s new president makes open market purchase of company shares

Titan starts Profound Medical at buy; PT $12

Profound strengthens leadership team with appointment of Richard Fabian as president

Profound’s new real-time interventional MRI software to pave the way for full ‘TULSA days’

Profound launches ‘Let’s Huddle’, a global community supporting men through prostate care

Incisionless TULSA Procedure for prostate cancer demonstrated statistically significant superior penile length preservation compared to Robotic Radical Prostatectomy at 1 month

Subscribe